Pharmafile Logo
Pharmafocus logo
Advanced Search

GLP-1

Showing 11 posts of 11 posts found.

novo_flag

FDA approves Novo Nordisk’s Victoza for children with type 2 diabetes

June 18, 2019
Manufacturing and Production GLP-1, Novo Nordisk, Victoza, diabetes, liraglutide

The FDA has approved Novo Nordisk’s Victoza (liraglutide) for paediatric patients aged 10 years and older with type 2 diabetes. …

News

Novo Nordisk’s oral diabetes drug safe and effective

June 12, 2019
Research and Development GLP-1, Novo Nordisk, diabetes, pharma, samgalutide

Novo Nordisk’s oral diabetes drug semaglutide is safe for those at high risk of cardiovascular complications, according to the results …

News

Study supports GLP-1 agonists for weight loss

January 10, 2012
Research and Development, Sales and Marketing GLP-1, Novo Nordisk, Sanofi, diabetes, lilly

An independent study by academics has concluded that GLP-1 agonist drugs help patients to lose weight – with the effect …

News

GSK diabetes drug fails head-to-head against Victoza

November 16, 2011
Sales and Marketing GLP-1, Victoza, albiglutide, diabetes

GlaxoSmithKline’s long-acting diabetes drug albiglutide has failed in a head-to-head trial against Novo Nordisk’s Victoza. Albiglutide is an injectable glucagon-like …

News

Byetta approved for use with insulin

October 19, 2011
Amylin, GLP-1, diabetes, lilly

The FDA has approved the use of Lilly and Amylin’s diabetes treatment Byetta as an add-on therapy to insulin glargine.The …

News

Fresh scrutiny for new diabetes drugs

September 15, 2011
Sales and Marketing Byetta, GLP-1, Januvia, Merck, Novo Nordisk, Victoza, diabetes

Merck’s Januvia and Lilly’s Byetta face renewed safety questions this week as the European Association for the Study of Diabetes …

News

Future of Roche diabetes trial uncertain

September 14, 2010
Research and Development GLP-1, Roche, taspoglutide

Roche has admitted it does not know when phase III trials of the investigational type II diabetes drug taspoglutide will …

News

Lixisenatide scores in phase III trial

April 15, 2010
Research and Development GLP-1, Lixisenatide, diabetes

Sanofi-Aventis’ novel, once-daily diabetes treatment lixisenatide has successfully met its phase III glucose blood level and glycaemic control endpoints. The …

News

Roche diabetes trial proves promising

February 11, 2010
Research and Development GLP-1, Roche, diabetes, taspoglutide

Phase III results for Roche’s once-weekly injectable drug taspoglutide have shown a positive effect on reducing blood glucose compared with …

News
Novo Nordisk HQ

Pancreatitis concerns take shine off Victoza approval

January 28, 2010
Sales and Marketing GLP-1, Novo Nordisk, Victoza

The FDA has approved Novo Nordisk’s Victoza a new once-daily injection for patients with type II diabetes. The drug will …

News

Victoza pill trial begins

January 19, 2010
Research and Development, Sales and Marketing GLP-1, Novo Nordisk, Victoza, diabetes, type II

A promising new diabetes treatment which can be taken as a pill instead of as an injection has just begun …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026